Using Immunotherapy Combinations in Hepatocellular Carcinoma

home / case-based-roundtable-series / using-immunotherapy-combinations-in-hepatocellular-carcinoma

This roundtable series reviews immunotherapy in patients with unresectable hepatocellular carcinoma as first-line treatment, as discussed by key opinion leaders and participants at virtual live events.

The Expansion of Treatment in the Firstline Setting of HCC

The Expansion of Treatment in the Firstline Setting of HCC

Richard D. Kim, MD
December 22nd 2022

Richard Kim, MD, walks through options in the frontline setting for patients with advanced staged hepatocellular carcinoma and how newer treatments have impacted this patient population.

Phase 3 HIMALAYA Trial Shows OS Benefit of Durvalumab in HCC

Phase 3 HIMALAYA Trial Shows OS Benefit of Durvalumab in HCC

Milind Javle, MD
January 18th 2023

Milind Javle, MD, discusses the phase 3 HIMALAYA study of durvalumab and tremelimumab in patients with locally advanced or metastatic hepatocellular cancer.